IL2 and nonpapillary renal cell carcinoma: PIVOT-09 is being conducted to examine the effect of bempegaldesleukin (IL-2 agonist) in combination with nivolumab versus either sunitinib or cabozantinib, and this clinical trial will compare the ORR and OS in an intermediate or poor-risk group of untreated ccRCC patients.